Danaher will acquire all outstanding Masimo shares for $180 per share in cash, valuing the company at roughly $9.9 billion including assumed debt and net cash. The purchase price implies an 18x multiple of estimated 2027 EBITDA, or 15x when including the full benefit of expected annual synergies by year five. Shareholder approval and regulatory clearances are required for closing.

The acquisition is projected to be accretive to Danaher's adjusted diluted net earnings per share by $0.15–$0.20 in the first full year, ramping up to $0.70 by the fifth year post-close. Danaher forecasts EBITDA for the combined Masimo business to exceed $530 million in 2027, along with $125 million in annual cost synergies and $50 million in annual revenue synergies by year five. Masimo is expected to drive high-single-digit core revenue growth within Danaher's Diagnostics segment over the long term.

Masimo will operate as a standalone company within Danaher's Diagnostics segment alongside Radiometer, Leica Biosystems, Cepheid, and Beckman Coulter. The deal is slated to close in the second half of 2026, funding the transaction through cash on hand and debt financing. Danaher plans to leverage its Business System and global scale to expand Masimo’s pulse oximetry and patient monitoring solutions in acute care settings.